Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the long-term outlook, several have cut target prices and earnings estimates, citing near-term execution risks and slower product ramp-up.
Dr Reddy’s pauses weight loss drug on quality fears
Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the active pharmaceutical ingredient manufacturing scale-up. The company assures that already supplied market products remain safe for patient use. Torrent Pharmaceuticals and USV Ltd are recalling some semaglutide batches sourced from Dr Reddy's. Commercial supplies are expected to resume after the issue is resolved and validation is complete.
Generics must not be imperiled over data protection: Satish Reddy, Chairman, Dr Reddy's Laboratories
Dr Reddy's chairman, Satish Reddy, has raised concerns about compromising India's competitive edge in generics for foreign investments. He stresses the importance of aligning capital with developmental needs and enhancing collaboration between academia and industry. Advocating for a national mission akin to China's, he highlights the necessity of structured government procurement to stimulate drug innovation and underscores AI's transformative role in drug discovery, contingent on adaptive regulatory systems.
Stocks to Watch today: HCL Tech, HDFC Bank, Turtlemint, Hexaware Tech, IRFC
Stocks to Watch today, June 29: Tata Motors PV, Torrent Power, Dr Reddy's Laboratories, Aurobindo Pharma, KEC International, and Adani Ports are among the top stocks to watch during today's trade
Dr Reddy’s receives Form 483 with 7 observations after USFDA inspection at Hyderabad facility
Shares of Dr Reddy's Laboratories Ltd ended at ₹1,351.00, up by ₹22.65, or 1.71%, on the BSE.
India needs innovation at scale to fulfill ambition of becoming global discovery hub: Dr Reddy's
India must shift from minor advancements to large-scale innovation to become a global discovery hub, according to Dr. Reddy's Laboratories Chairman Satish Reddy. He emphasized the need for robust translational research pathways to ensure scientific breakthroughs benefit patients. The company's white paper highlights that stronger collaboration between academia, industry, and government is crucial for translating research into accessible healthcare solutions and overcoming existing challenges.
Dr Reddy's Labs Q1 Results: Date, Dividend, Share Price History, And More
Dr Reddy's Laboratories Ltd. saw an 86% YoY (year-on-year) plunge in Q4 net profit.
Nomura expects shares of this drugmaker to rise 37% on renewed branded generics, consumer biz focus
Nomura, in its note, said that Dr. Reddy's Laboratories has sharpened its focus on branded generics and consumer business, a shift reflected in acquisitions, organic investments and recent changes to the management council.
Dr. Reddy's Labs oncology drug Bosutinib Tablets in United States
Dr. Reddy's Laboratories has announced the first-to-market launch of Bosutinib Tablets 400 mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio.
Buy, Sell Or Hold: IRCTC, SBI, Hindustan Copper, M&M, Paras Defence, Dr Reddy's Laboratories — Ask Profit
Buy Sell Hold
Dr Reddy’s launches oral semaglutide in India
Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This launch expands access to advanced diabetes care. Dr Reddys is the second Indian company to introduce oral semaglutide domestically. The company is committed to reliable supply and consistent quality for Indian patients.
Stocks to Watch for May 21: Aditya Birla Capital, Dr Reddy's Lab, Jubilant Food, Bosch India and more
From Dr Reddy's Laboratories announcing the launch of its oral semaglutide biosimilar in India under the brand name Obeda to Whirlpool of India Ltd reporting a 32.7% year-on-year decline in net profit Q4, here are some stocks to track ahead of Thursday trading session.